Faculty
Hematology Division
Alphabetical list (active faculty):   
Stephen T. Oh

Stephen T. Oh, MD, PhD

Associate Professor

Department of Medicine

Hematology Division

Department of Pathology & Immunology

Research Interests

  • Myeloproliferative neoplasms

Contact

Peer-reviewed Publications

  • Pevonedistat Targets Malignant Cells in Myeloproliferative Neoplasms in Vitro and in Vivo Via NFkB Pathway Inhibition
    Kong T, Brunelli Albertoni Laranjeira A, Collins T, De Togni ES, Wong AJ, Fulbright MC, Ruzinova M, Celik H, Challen G, Fisher DAC, Oh ST
    Blood Adv 2021 Oct 13; [Epub ahead of print]
  • Retrospective Analysis of Pacritinib in Patients With Myelofibrosis and Severe Thrombocytopenia
    Verstovsek S, Mesa R, Talpaz M, Kiladjian JJ, Harrison CN, Oh ST, Vannucchi AM, Rampal R, Scott BL, Buckley SA, Craig AR, Roman-Torres K, Mascarenhas JO
    Haematologica 2021 Sep 23; [Epub ahead of print]
  • A Humanized Animal Model Predicts Clonal Evolution and Therapeutic Vulnerabilities in Myeloproliferative Neoplasms
    Celik H, Krug E, Zhang CR, Han W, Issa N, Koh WK, Bjeije H, Kukhar O, Allen M, Li T, Fisher DA, Fowles JS, Wong TN, Stubbs MC, Koblish HK, Oh ST, Challen GA
    Cancer Discov 2021 Jun 30; [Epub ahead of print]
  • Co-Evolution of Tumor and Immune Cells During Progression of Multiple Myeloma
    Liu R, Gao Q, Foltz SM, Fowles JS, Yao L, Wang JT, Cao S, Sun H, Wendl MC, Sethuraman S, Weerasinghe A, Rettig MP, Storrs EP, Yoon CJ, Wyczalkowski MA, McMichael JF, Kohnen DR, King J, Goldsmith SR, O'Neal J, Fulton RS, Fronick CC, Ley TJ, Jayasinghe RG, Fiala MA, Oh ST, DiPersio JF, Vij R, Ding L
    Nat Commun 2021 May 7;12(1):2559
  • MOMENTUM: Momelotinib Vs Danazol in Patients With Myelofibrosis Previously Treated With JAKi Who Are Symptomatic and Anemic
    Verstovsek S, Chen CC, Egyed M, Ellis M, Fox L, Goh YT, Gupta V, Harrison C, Kiladjian JJ, Lazaroiu MC, Mead A, McLornan D, McMullin MF, Oh ST, Perkins A, Platzbecker U, Scheid C, Vannucchi A, Yoon SS, Kowalski MM, Mesa RA
    Future Oncol 2021 Apr;17(12):1449-1458
  • Defining Phenotypic and Functional Heterogeneity of Glioblastoma Stem Cells by Mass Cytometry
    Galdieri L, Jash A, Malkova O, Mao DD, DeSouza P, Chu YE, Salter A, Campian JL, Naegle KM, Brennan CW, Wakimoto H, Oh ST, Kim AH, Chheda MG
    JCI Insight 2021 Feb 22;6(4)
  • Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia
    Barnell EK, Newcomer KF, Skidmore ZL, Krysiak K, Anderson SR, Wartman LD, Oh ST, Welch JS, Stockerl-Goldstein KE, Vij R, Cashen AF, Pusic I, Westervelt P, Abboud CN, Ghobadi A, Uy GL, Schroeder MA, DiPersio JF, Politi MC, Spencer DH, Duncavage EJ, Ley TJ, Griffith M, Jacoby MA, Griffith OL
    JCO Precis Oncol 2021 Jan 14;5
  • Determining the Recommended Dose of Pacritinib: Results From the PAC203 Dose-Finding Trial in Advanced Myelofibrosis
    Gerds AT, Savona MR, Scott BL, Talpaz M, Egyed M, Harrison CN, Yacoub A, Vannucchi A, Mead AJ, Kiladjian JJ, O'Sullivan J, Garcia-Gutierrez V, Bose P, Rampal RK, Miller CB, Palmer J, Oh ST, Buckley SA, Mould DR, Ito K, Tyavanagimatt S, Smith JA, Roman-Torres K, Devineni S, Craig AR, Mascarenhas JO
    Blood Adv 2020 Nov 24;4(22):5825-5835
  • ACVR1/JAK1/JAK2 Inhibitor Momelotinib Reverses Transfusion Dependency and Suppresses Hepcidin in Myelofibrosis Phase 2 Trial
    Oh ST*, Talpaz M, Gerds AT, Gupta V, Verstovsek S, Mesa R, Miller CB, Rivera CE, Fleischman AG, Goel S, Heaney ML, O'Connell C, Arcasoy MO, Zhang Y, Kawashima J, Ganz T, Kowalski M, Brachmann CB (*corresponding author)
    Blood Adv 2020 Sep 22;4(18):4282-4291
  • Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study
    Grunwald MR, Kuter DJ, Altomare I, Burke JM, Gerds AT, Walshauser MA, Savona MR, Stein B, Oh ST, Colucci P, Parasuraman S, Paranagama D, Mesa R
    Clin Lymphoma Myeloma Leuk 2020 Apr;20(4):219-225
  • Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia
    Dao KT, Gotlib J, Deininger MMN, Oh ST, Cortes JE, Collins RH Jr, Winton EF, Parker DR, Lee H, Reister A, Schultz, Savage S, Stevens, Brockett C, Subbiah N, Press RD, Raess PW, Cascio M, Dunlap J, Chen Y, Degnin C, Maxson JE, Tognon CE, Macey T, Druker BJ, Tyner JW
    J Clin Oncol 2020 Apr 1;38(10):1006-1018
  • Genomic Landscape of Neutrophilic Leukemias of Ambiguous Diagnosis
    Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister Schultz A, Long N, White L, Carlos A, Henson R, Lin C, Searles R, Collins RH, DeAngelo DJ, Deininger MW, Dunn T, Hein T, Luskin MR, Medeiros BC, Oh ST, Pollyea DA, Steensma DP, Stone RM, Druker BJ, McWeeney SK, Maxson JE, Gotlib JR, Tyner JW
    Blood 2019 Sep 12;134(11):867-879
  • Cytokine Production in Myelofibrosis Exhibits Differential Responsiveness to JAK-STAT, MAP Kinase, and NFkappaB Signaling
    Fisher DAC, Miner CA, Engle EK, Hu H, Collins TB, Zhou A, Allen MJ, Malkova ON, Oh ST
    Leukemia 2019 Aug;33(8):1978-1995
  • Young Versus Old Age at Diagnosis Confers Distinct Genomic Profiles in Patients With Polycythemia Vera
    Fowles JS, How J, Allen MJ, Oh ST
    Leukemia 2019 Jun;33(6):1522-1526
  • Identification of Functionally Primitive and Immunophenotypically Distinct Subpopulations in Secondary Acute Myeloid Leukemia by Mass Cytometry
    Bandyopadhyay S, Fowles JS, Yu L, Fisher DAC, Oh ST
    Cytometry B Clin Cytom 2019 Jan;96(1):46-56
  • Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States
    Grunwald MR, Stein BL, Boccia RV, Oh ST, Paranagama D, Parasuraman S, Colucci P, Mesa R
    Clin Lymphoma Myeloma Leuk 2018 Dec;18(12):788-795e2
  • A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia
    Spiciarich DR, Oh ST, Foley A, Hughes SB, Mauro MJ, Abdel-Wahab O, Press RD, Viner R, Thompson SL, Chen Q, Azadi P, Bertozzi CR, Maxson JE
    Cancer Res 2018 Dec 15;78(24):6762-6770
  • JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor Cells
    Celik H, Koh WK, Kramer AC, Ostrander EL, Mallaney C, Fisher DAC, Xiang J, Wilson WC, Martens A, Kothari A, Fishberger G, Tycksen E, Karpova D, Duncavage EJ, Lee Y, Oh ST, Challen GA
    Cancer Cell 2018 Nov 12;34(5):741-756e8
  • High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling During Successful Immune-Checkpoint Cancer Therapy
    Gubin MM, Esaulova E, Ward JP, Malkova ON, Runci D, Wong P, Noguchi T, Arthur CD, Meng W, Alspach E, Medrano RFV, Fronick C, Fehlings M, Newell EW, Fulton RS, Sheehan KCF, Oh ST, Schreiber RD, Artyomov MN
    Cell 2018 Nov 1;175(4):1014-1030e19
  • Distinct Clinical, Laboratory and Molecular Features of Myeloproliferative Neoplasm Patients With Splanchnic Vein Thrombosis
    How J, Trinkaus KM, Oh ST
    Br J Haematol 2018 Oct;183(2):310-313
  • Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States
    Mesa R, Boccia RV, Grunwald MR, Oh ST, Colucci P, Paranagama D, Parasuraman S, Stein BL
    Clin Lymphoma Myeloma Leuk 2018 Sep;18(9):590-596
  • Identification of Enhanced IFN-Gamma Signaling in Polyarticular Juvenile Idiopathic Arthritis With Mass Cytometry
    Throm AA, Moncrieffe H, Orandi AB, Pingel JT, Geurs TL, Miller HL, Daugherty AL, Malkova ON, Lovell DJ, Thompson SD, Grom AA, Cooper MA, Oh ST, French AR
    JCI Insight 2018 Aug 9;3(15)
  • Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
    Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, Hussaini M, Mirza AS, Komrokji RS, Oh S, Mascarenhas J, Najfeld V, Subbiah V, Kantarjian H, Garcia-Manero G, Verstovsek S, Daver N
    Leuk Lymphoma 2018 Jul;59(7):1672-1676
  • Patterns of Infectious Complications in Acute Myeloid Leukemia and Myelodysplastic Syndromes Patients Treated With 10-Day Decitabine Regimen
    Ali AM, Weisel D, Gao F, Uy GL, Cashen AF, Jacoby MA, Wartman LD, Ghobadi A, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Schroeder MA, Westervelt P, DiPersio JF, Welch JS
    Cancer Med 2017 Dec;6(12):2814-2821
  • Cholesterol Esterification Inhibition and Imatinib Treatment Synergistically Inhibit Growth of BCR-ABL Mutation-Independent Resistant Chronic Myelogenous Leukemia
    Bandyopadhyay S, Li J, Traer E, Tyner JW, Zhou A, Oh ST*, Cheng JX* (*Co-corresponding authors)
    PLoS One 2017 Jul 18;12(7):e0179558
  • A Phase 2 Study of Simtuzumab in Patients With Primary, Post-Polycythaemia Vera or Post-Essential Thrombocythaemia Myelofibrosis
    Verstovsek S, Savona MR, Mesa RA, Dong H, Maltzman JD, Sharma S, Silverman J, Oh ST, Gotlib J
    Br J Haematol 2017 Mar;176(6):939-949
  • Mass Cytometry Analysis Reveals Hyperactive NF Kappa B Signaling in Myelofibrosis and Secondary Acute Myeloid Leukemia
    Fisher DAC, Malkova O, Engle EK, Miner CA, Fulbright MC, Behbehani GK, Collins TB, Bandyopadhyay S, Zhou A, Nolan GP, Oh ST
    Leukemia 2017 Sep;31(9):1962-1974
  • TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
    Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ
    N Engl J Med 2016 Nov 24;375(21):2023-2036
  • Cytokine-Induced Memory-Like Natural Killer Cells Exhibit Enhanced Responses Against Myeloid Leukemia
    Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, Leong JW, Abdel-Latif S, Schneider SE, Willey S, Neal CC, Yu L, Oh ST, Lee YS, Mulder A, Claas F, Cooper MA, Fehniger TA
    Sci Transl Med 2016 Sep 21;8(357):357ra123
  • Concurrent MPL W515L and Y591D Mutations in a Patient With Myelofibrosis
    Rashidi A, Heusel JW, Oh ST
    Blood Cells Mol Dis 2016 Sep;60:1-2
  • Clinical Improvement With JAK2 Inhibition in Chuvash Polycythemia
    Zhou AW, Knoche EM, Engle EK, Ban-Hoefen M, Kaiwar C, Oh ST
    N Engl J Med 2016 Aug 4;375(5):494-6
  • Concomitant JAK2 V617F-Positive Polycythemia Vera and BCR-ABL-Positive Chronic Myelogenous Leukemia Treated With Ruxolitinib and Dasatinib
    Zhou A, Knoche EM, Engle EK, Fisher DA, Oh ST
    Blood Cancer J 2015 Oct 2;5:e351
  • Brief Report: Chikungunya Viral Arthritis in the United States: A Mimic of Seronegative Rheumatoid Arthritis
    Miner JJ, Aw Yeang HX, Fox JM, Taffner S, Malkova ON, Oh ST, Kim AH, Diamond MS, Lenschow DJ, Yokoyama WM
    Arthritis Rheumatol 2015 May;67(5):1214-20
  • Clonal Evolution Revealed by Whole Genome Sequencing in a Case of Primary Myelofibrosis Transformed to Secondary Acute Myeloid Leukemia
    Engle EK, Fisher DA, Miller CA, McLellan MD, Fulton RS, Moore DM, Wilson RK, Ley TJ, Oh ST
    Leukemia 2015 Apr;29(4):869-876
  • Disseminated Tuberculosis Associated With Ruxolitinib
    Hopman RK, Lawrence SJ, Oh ST
    Leukemia 2014 Aug;28(8):1750-1
  • Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML
    Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW
    N Engl J Med 2013 May 9;368(19):1781-90
  • Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening
    Tyner JW, Yang WF, Bankhead A 3rd, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, Den Boer ML, van den Heuvel-Eibrink MM, O'Hare T, Druker BJ, Loriaux MM
    Cancer Res 2013 Jan 1;73(1):285-296
  • A Novel Splice Donor Mutation in the Thrombopoietin Gene Leads to Exon 2 Skipping in a Filipino Family With Hereditary Thrombocythemia
    Zhang B, Ng D, Jones C, Oh ST, Nolan GP, Salehi S, Wong W, Zehnder JL, Gotlib J
    Blood 2011 Dec 22;118(26):6988-90
  • LNK Mutation Studies in Blast-Phase Myeloproliferative Neoplasms, and in Chronic-Phase Disease With TET2, IDH, JAK2 or MPL Mutations
    Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi A
    Leukemia 2010 Oct;24(10):1713-8
  • Novel Mutations in the Inhibitory Adaptor Protein LNK Drive JAK-STAT Signaling in Patients With Myeloproliferative Neoplasms
    Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs KD Jr, Merker JD, Zehnder JL, Nolan GP, Gotlib J
    Blood 2010 Aug 12;116(6):988-92
  • Design and Evaluation of a Real-Time PCR Assay for Quantification of JAK2 V617F and Wild-Type JAK2 Transcript Levels in the Clinical Laboratory
    Merker JD, Jones CD, Oh ST, Schrijver I, Gotlib J, Zehnder JL
    J Mol Diagn 2010 Jan;12(1):58-64
  • Roles of the E6 and E7 Proteins in the Life Cycle of Low-Risk Human Papillomavirus Type 11
    Oh ST, Longworth MS, Laimins LA
    J Virol 2004 Mar;78(5):2620-6
  • Cellular Changes Induced by Low-Risk Human Papillomavirus Type 11 in Keratinocytes That Stably Maintain Viral Episomes
    Thomas JT, Oh ST, Terhune SS, Laimins LA
    J Virol 2001 Aug;75(16):7564-71
  • Telomerase Activation by Human Papillomavirus Type 16 E6 Protein: Induction of Human Telomerase Reverse Transcriptase Expression Through Myc and GC-Rich Sp1 Binding Sites
    Oh ST, Kyo S, Laimins LA
    J Virol 2001 Jun;75(12):5559-66

Reviews, Book Chapters, and Commentaries

  • Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms
    Fisher DAC, Fowles JS, Zhou A, Oh ST
    Front Immunol 2021 Jun 1;12:683401
  • Myeloid/Lymphoid Neoplasms With Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
    Gerds AT, Gotlib J, Bose P, Deininger MW, Dunbar A, Elshoury A, George TI, Gojo I, Gundabolu K, Hexner E, Hobbs G, Jain T, Jamieson C, Kuykendall AT, McMahon B, Mohan SR, Oehler V, Oh S, Pardanani A, Podoltsev N, Ranheim E, Rein L, Salit R, Snyder DS, Stein BL, Talpaz M, Thota S, Vachhani P, Wadleigh M, Walsh K, Ward DC, Bergman MA, Sundar H
    J Natl Compr Canc Netw 2020 Sep;18(9):1248-1269
  • Unraveling the Architecture of Classic Hodgkin Lymphoma One Cell at a Time
    Fisher DAC, Oh ST
    Cancer Discov 2020 Mar;10(3):342-344
  • Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
    Gotlib J, Gerds AT, Bose P, Castells MC, Deininger MW, Gojo I, Gundabolu K, Hobbs G, Jamieson C, McMahon B, Mohan SR, Oehler V, Oh S, Padron E, Pancari P, Papadantonakis N, Pardanani A, Podoltsev N, Rampal R, Ranheim E, Rein L, Snyder DS, Stein BL, Talpaz M, Thota S, Wadleigh M, Walsh K, Bergman MA, Sundar H
    J Natl Compr Canc Netw 2018 Dec;16(12):1500-1537
  • Neutralize the Neutrophils! Neutrophil Beta1/Beta2 Integrin Activation Contributes to JAK2-V617F-Driven Thrombosis
    Oh ST
    J Clin Invest 2018 Oct 1;128(10):4248-4250
  • NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018
    Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, McMahon B, Mohan SR, Oh S, Padron E, Papadantonakis N, Pancari P, Podoltsev N, Rampal R, Ranheim E, Reddy V, Rein LAM, Scott B, Snyder DS, Stein BL, Talpaz M, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H
    J Natl Compr Canc Netw 2017 Oct;15(10):1193-1207
  • Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: A Review of the Recent Literature
    Zhou A, Afzal A, Oh ST
    Curr Hematol Malig Rep 2017 Oct;12(5):397-405
  • Analysis of Signaling Networks at the Single-Cell Level Using Mass Cytometry
    Bandyopadhyay S, Fisher DAC, Malkova O, Oh ST
    Methods Mol Biol 2017;1636:371-392
  • Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Pathophysiology and Molecular Mechanisms of Disease
    How J, Zhou A, Oh ST
    Ther Adv Hematol 2017 Mar;8(3):107-118
  • Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
    Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, Klisovic RB, Kropf P, Mohan SR, Oh S, Padron E, Podoltsev N, Pollyea DA, Rampal R, Rein LA, Scott B, Snyder DS, Stein BL, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H
    J Natl Compr Canc Netw 2016 Dec;14(12):1572-1611
  • Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F
    Stein BL*, Oh ST*, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK, Abboud CN, Adler K, Heaney ML, Jabbour EJ, Komrokji RS, Moliterno AR, Ritchie EK, Rice L, Mascarenhas J, Hoffman R (*Equal contributions)
    J Clin Oncol 2015 Nov 20;33(33):3953-60
  • Historical Views, Conventional Approaches, and Evolving Management Strategies for Myeloproliferative Neoplasms
    Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, Jamieson C, Pollyea DA, Scott B, Wadleigh M, Levine R, Komrokji R, Klisovic R, Gundabolu K, Kropf P, Wetzler M, Oh ST, Ribeiro R, Paschal R, Mohan S, Podoltsev N, Prchal J, Talpaz M, Snyder D, Verstovsek S, Mesa RA
    J Natl Compr Canc Netw 2015 Apr;13(4):424-34
  • Prognostication in MF: From CBC to Cytogenetics to Molecular Markers
    Zhou A, Oh ST
    Best Pract Res Clin Haematol; Epub 2014 Jul 18
  • Pathology Consultation on Myeloproliferative Neoplasms
    Schmidt AE, Oh ST
    Am J Clin Pathol 2012 Jul;138(1):12-19
  • When the Brakes Are Lost: LNK Dysfunction in Mice, Men, and Myeloproliferative Neoplasms
    Oh ST
    Ther Adv Hematol 2011 Feb;2(1):11-9
  • JAK2 V617F and Beyond: Role of Genetics and Aberrant Signaling in the Pathogenesis of Myeloproliferative Neoplasms
    Oh ST, Gotlib J
    Expert Rev Hematol 2010 Jun;3(3):323-37
  • Antiangiogenic Therapy in Myelodysplastic Syndromes: Is There a Role?
    Oh ST, Gotlib J
    Curr Hematol Malig Rep 2008 Jan;3(1):10-8
  • Molecular Pathogenesis of Human Papillomavirus Infections
    Oh ST, Laimins LA
    In: Cervical cancer: from etiology to prevention (Shah KV, Rohan TE, eds); Kluwer Academic Publishers 2004; pp 101-118